StockNews.com began to cover the shares of Nymox Pharmaceutical (NASDAQ: NYMX- Get a rating) in a research note published Saturday. The brokerage has set a “sell” rating on the shares of the biopharmaceutical company.
NYMX stock opened at $1.21 on Friday. The company’s 50-day simple moving average is $1.58 and its 200-day simple moving average is $1.63. Nymox Pharmaceutical has a 52 week low of $0.94 and a 52 week high of $2.87. The company has a market capitalization of $102.24 million, a P/E ratio of -8.07 and a beta of 1.18.
A number of institutional investors have recently changed their stock portfolios. Private Advisor Group LLC increased its stake in Nymox Pharmaceutical by 447.3% in Q3. Private Advisor Group LLC now owns 170,200 shares of the biopharmaceutical company valued at $350,000 after acquiring an additional 139,100 shares in the last quarter. Millennium Management LLC increased its stake in Nymox Pharmaceutical by 1,834.9% in Q2. Millennium Management LLC now owns 323,364 shares of the biopharmaceutical company valued at $511,000 after acquiring 306,652 additional shares in the last quarter. Morgan Stanley increased its stake in Nymox Pharmaceutical by 15.9% in the second quarter. Morgan Stanley now owns 76,239 shares of the biopharmaceutical company valued at $120,000 after acquiring 10,471 additional shares in the last quarter. Geode Capital Management LLC increased its equity stake in Nymox Pharmaceutical by 21.8% during the 3rd quarter. Geode Capital Management LLC now owns 50,731 shares of the biopharmaceutical company worth $104,000 after purchasing an additional 9,086 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Nymox Pharmaceutical shares by 71.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 48,736 shares of the biopharmaceutical company worth $77,000 after buying 20,236 more shares in the last quarter. 1.59% of the shares are currently held by hedge funds and other institutional investors.
About Nymox Pharmaceutical (Get a rating)
Nymox Pharmaceutical Corp. is a biopharmaceutical company that engages in the research and development of products for the aging population. Its products include NicAlert and TobacAlert, as well as NX-1207 for the treatment of localized low-grade prostate cancer. It operates through the following geographic segments: Canada, United States and Europe.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Nymox Pharmaceutical right now?
Before you consider Nymox Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Nymox Pharmaceutical wasn’t on the list.
Although Nymox Pharmaceutical currently has an “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here